首页|不同拮抗剂在促性腺激素释放激素拮抗剂方案中的应用

不同拮抗剂在促性腺激素释放激素拮抗剂方案中的应用

扫码查看
目的 比较促性腺激素释放激素拮抗剂(GnRH-ant)方案中使用国产西曲瑞克与进口加尼瑞克的IVF/ICSI-ET临床结局。方法 收集2022年12月至2023年8月在我院采用拮抗剂方案行IVF/ICSI-ET助孕治疗的340个周期临床资料,根据患者药物使用情况分为西曲瑞克组(n=170)和加尼瑞克组(n=170),比较两组患者的基本资料、促排卵情况及临床妊娠结局。结果 两组患者的年龄、体质量指数(BMI)、基础性激素水平等基本资料比较均无显著性差异(P>0。05)。两组患者的Gn天数、Gn用量、HCG日性激素水平、获卵数、MⅡ卵数、总受精率、卵裂期优胚数、囊胚形成数、优质囊胚数、中重度卵巢过度刺激综合征(OHSS)发生率、LH升高(>10 U/L)率、HCG日LH<1 U/L发生率比较均无显著性差异(P>0。05)。与加尼瑞克组比较,西曲瑞克组拮抗剂总费用显著降低[(1 383。49±495。71)元vs。(1 762。22±608。66)元,P<0。05]。西曲瑞克组鲜胚移植61个周期,加尼瑞克组鲜胚移植56个周期,两组鲜胚移植周期的妊娠结局指标(HCG阳性率、临床妊娠率、种植率、多胎率、异位妊娠率、早期流产率)比较均无显著性差异(P>0。05)。结论 国产西曲瑞克和进口加尼瑞克用于拮抗剂方案促排卵治疗时,两者具有相似的抑制早排卵效果和良好临床妊娠结局,国产西曲瑞克治疗药物费用较低,临床实践中可以根据患者的具体情况和经济条件进行综合评价。
Application of different antagonists in GnRH antagonist regimens
Objective:To compare the clinical outcomes of IVF/ICSI-ET with injectable cetrorelix versus ganirelix acetate in a GnRH antagonist regimen.Methods:The clinical data of 340 cycles of IVF/ICSI-ET fertility treatment with the antagonist regimen in Chengdu Jinjiang District Maternal and Child Health Hospital from December 2022 to August 2023 were retrospectively analyzed.According to the use of antagonist drugs,the cycles were divided into the cetrorelix group(n=170)and the ganirelix group(n=170).The basic characteristics,the ovulation promotion and clinical pregnancy outcomes were compared between the cetrorelix group and the ganirelix group.Results:There were no significant differences in age,body mass index(BMI),basal levels of sex hormone between the two groups(P>0.05).There were no significant differences in the number of Gn days,Gn dosage,sex hormone levels on HCG day,the number of retrieved oocytes,the number of M]]oocytes,total fertilization rate,the number of high-quality cleavage embryos,the number of blastocysts formed,the number of high-quality blastocysts,the incidence of moderate-severe OHSS,the rate of LH elevation(>10 U/L)and the rate of less than 1 U/L of LH level on HCG day between the two groups(P>0.05).The total cost of antagonist use was significantly lower in the cetrorelix group compared with the ganirelix group[RMB(1 383.49±495.71)vs.RMB(1 762.22±608.66),P<0.05].There were no significant differences in HCG positive rate,clinical pregnancy rate,the implantation rate,multiple pregnancy rate,ectopic pregnancy rate,early miscarriage rate in the cetrorelix group with 61 cycles of fresh embryo transfer and the ganirelix group with 56 cycles of fresh embryo transfer(P>0.05).Conclusions:Domestic cetrorelix and imported ganirelix in GnRH antagonist regimen had similar inhibition effect of early ovulation,with good clinical pregnancy outcomes in both groups.The cost of domestic cetrorelix was lower.A comprehensive evaluation can be conducted based on the specific situation and economic conditions of patients in clinical practice.

IVF/ETGnRH antagonistGanirelixCetrorelix

何芳芳、胡文惠

展开 >

成都市锦江区妇幼保健院生殖中心,成都 610066

体外受精-胚胎移植 促性腺激素释放激素拮抗剂 西曲瑞克 加尼瑞克

2024

生殖医学杂志
北京协和医院 国家人口计生委科学技术研究所

生殖医学杂志

CSTPCD
影响因子:1.24
ISSN:1004-3845
年,卷(期):2024.33(9)